SUMO1

Across TCGA pan-cancer cohorts, SUMO1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SUMO1 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SUMO1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUMO1 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

PDAC, LUAD, and COAD are the cancer types where SUMO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.301	0.577	<.001	48	view →
LUAD	OS	Median	III,IV	0.358	0.753	.010	9	view →
COAD	DFS	Median	All	1.000	0.884	.042	6	view →
LSCC	DFS	Tertile	All	0.856	0.999	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SUMO1–PDAC (DFS)

Open the PDAC breakdown →